Botulinum toxin type A

Botulinum neurotoxin type A is a two-chain protein: the heavy chain binds SV2 receptors on the presynaptic terminal and mediates internalisation, and the light chain is a zinc-dependent endopeptidase that cleaves nine residues from the C-terminus of SNAP-25. Once SNAP-25 is cut, the SNARE complex cannot assemble and vesicle fusion stops completely — this is why the effect is functional denervation rather than the partial, competitive interference that peptides like Argireline aim for. Recovery takes 3-4 months and depends on axonal sprouting and eventual restoration of the original terminal, not on the toxin wearing off. The distinction that matters for this class: Argireline occupies a binding site reversibly at whatever concentration reaches the muscle, while botulinum toxin destroys the substrate catalytically at picomolar amounts, injected directly into the target.

Targets: SNAP-25, SV2 receptor, SNARE complex, Neuromuscular junction acetylcholine release

• · Dosed in units of biological activity, not micrograms, and units are not interchangeable between brands. The licensed onabotulinumtoxinA glabellar dose is 20 units split across five injection points. Dysport units are roughly 2.5-3x onabotulinumtoxinA units for the same effect.
• · Licensed onabotulinumtoxinA dose is 24 units total, 12 per side across three points.
• · Licensed onabotulinumtoxinA dose is 20 units across five points, given alongside 20 units in the glabellar complex. Treating frontalis without the glabella is a common cause of brow ptosis.

Work out your exact syringe units →

• very commonInjection-site bruising and tenderness— Resolves in a few days.
• commonHeadache— Usually in the first week.
• uncommonEyelid or brow ptosis— From diffusion into levator palpebrae or over-treatment of frontalis. Lasts weeks to months; apraclonidine drops help temporarily.
• uncommonAsymmetry or unwanted expression change— Often correctable with a small top-up at the two-week review.
• rareDistant spread of toxin effect— The FDA boxed warning. Dysphagia and breathing difficulty have been reported, overwhelmingly at therapeutic rather than cosmetic doses, but the warning applies to all uses.

• Infection at the proposed injection site.
• Known hypersensitivity to any botulinum toxin preparation or to human albumin in the formulation.
• Myasthenia gravis, Lambert-Eaton syndrome or amyotrophic lateral sclerosis — these patients are at markedly higher risk of systemic effects.
• Pregnancy and breastfeeding — no adequate data, and it is an entirely elective procedure.

• cautionaminoglycoside-antibiotics — Aminoglycosides impair neuromuscular transmission and can potentiate the toxin's effect.
• redundantargireline — Topical SNARE peptides add nothing to a muscle already chemically denervated.
• synergydermal-fillers — The standard combination approach — toxin for dynamic lines, filler for volume and static folds.

• · Two-week review appointment to assess symmetry and top up if needed.
• · Track treatment intervals; needing retreatment sooner than three months can indicate developing antibody resistance.

Prescription-only biologic approved for cosmetic use in the US, EU, UK and most jurisdictions. Must be administered by a qualified injector; unlicensed product and home injection have caused documented cases of iatrogenic botulism.

• Botox Cosmetic (onabotulinumtoxinA) FDA prescribing information (label)
• Carruthers et al., phase 3 randomised trials of onabotulinumtoxinA for glabellar lines (trial)

The reason this compound belongs in a cosmetic peptide class is that it is the only thing in it that reaches its target, and understanding why is the most useful comparison the site can make. The heavy chain C-terminal domain binds a dual receptor — a polysialoganglioside such as GT1b on the presynaptic membrane, then the luminal domain of synaptic vesicle protein 2, which is only exposed when a vesicle fuses and everts. That is an elegant piece of targeting: the toxin can only enter a nerve terminal that is actively releasing transmitter. It is taken up by endocytosis, the heavy chain N-terminal domain forms a channel in the acidified endosome, and the light chain translocates into the cytosol where the interchain disulfide is reduced. The light chain is then a zinc metalloprotease that cleaves nine residues from the C-terminus of SNAP-25. One enzyme molecule cleaves many SNAP-25 molecules — this is catalytic amplification, and it is exactly what a competitive peptide inhibitor like Argireline cannot do. A truncated SNAP-25 still enters SNARE complexes but produces a non-functional one that cannot drive fusion, so the block is dominant-negative rather than merely subtractive. Recovery requires the terminal to sprout new branches, form new active zones, and eventually for the original terminal to be restored, which takes three to four months. Put the comparison plainly: Argireline occupies a binding site reversibly at whatever fraction of 0.01% of an applied dose reaches viable epidermis; botulinum toxin destroys the substrate catalytically at picomolar concentrations, injected directly into the muscle. Those are not the same kind of intervention and no amount of formulation closes the gap.

Unlicensed product and home injection. There have been documented cases of iatrogenic botulism from counterfeit and improperly diluted product, and this is a genuine hospitalisation-and-antitoxin scenario rather than a cosmetic mishap. Buy from a licensed injector using licensed product; there is no safe home version of this. The clinical failure modes with a competent injector are mostly correctable: brow ptosis from over-treating frontalis, eyelid ptosis from diffusion into levator palpebrae which lasts weeks and responds partially to apraclonidine drops, and asymmetry which a small top-up at the two-week review usually fixes. The chronic failure mode is antibody resistance — retreatment intervals creeping shorter than three months, or a treatment simply not working, can indicate neutralising antibodies, and shortening intervals to chase effect makes it more likely. Keep intervals at three to four months and keep a record of them. And the expression-quality failure: over-treatment produces a face that reads as absent rather than rested, which is a dosing and injector-skill problem, not an inherent property of the drug.

1. —0 — First treatment: injectors typically start at the lower end of the licensed range. For onabotulinumtoxinA the licensed glabellar dose is 20 units across five points. You can always add units at the review; you cannot remove them.
2. —2 — Two-week review. Assess symmetry and residual movement at full effect, and top up asymmetries with small doses. This appointment is the single most valuable part of the protocol and most people skip it.
3. —12-16 — Retreatment. Do not shorten this interval to chase the last weeks of effect — shorter intervals raise the risk of neutralising antibody formation, more so with the higher-protein formulations.

• Synaptic vesicle protein 2 (SV2), particularly SV2C, plus polysialoganglioside co-receptor — High-affinity dual-receptor binding; the SV2 luminal domain is only accessible during vesicle exocytosis

  Activity-dependent entry — the toxin selectively enters terminals that are actively firing.

• SNAP-25 — Catalytic, not stoichiometric — one light chain cleaves many substrate molecules

  Cleaves nine residues from the SNAP-25 C-terminus. The truncated protein still enters SNARE complexes and poisons them, producing dominant-negative inhibition of vesicle fusion.

• Cholinergic autonomic terminals (off-target at cosmetic sites, on-target therapeutically) — Same mechanism

  The basis for hyperhidrosis and sialorrhoea indications, and for dry mouth and dry eye as side effects.

• Carruthers et al. multicentre double-blind randomised placebo-controlled study of botulinum toxin type A for glabellar lines (J Am Acad Dermatol) Phase 3 · 2002

  Efficacy and safety in glabellar lines. One of the registration trials that produced the cosmetic approval.

• Carruthers et al. double-blind placebo-controlled study of botulinum toxin type A for glabellar lines (Plast Reconstr Surg) Phase 3 · 2003

  Safety and efficacy in glabellar lines. The companion registration trial.

• SAKURA 1 and SAKURA 2: daxibotulinumtoxinA for glabellar lines (Plast Reconstr Surg) Phase 3, two multicentre randomised double-blind placebo-controlled studies · 2020

  Glabellar line severity. The trials behind the longer-duration daxibotulinumtoxinA formulation.

• Carruthers et al. phase 3 study of incobotulinumtoxinA free from complexing proteins in glabellar frown lines (Dermatol Surg) Phase 3 multicentre randomised · 2013

  Efficacy of a single dose of the complexing-protein-free formulation, which is the product marketed on lower antigenicity.

• Rzany et al. phase 3 non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for moderate to severe glabellar lines (Aesthetic Surgery Journal) Phase 3 non-inferiority, multicentre randomised double-blind placebo-controlled · 2020

  Non-inferiority of prabotulinumtoxinA to onabotulinumtoxinA. Head-to-head data of a kind that simply does not exist anywhere else in this class.

• Carruthers et al. repeated onabotulinumtoxinA treatments in crow's feet and glabellar lines (Dermatol Surg) Multicentre randomised double-blind placebo-controlled · 2015

  Efficacy and safety of repeated treatments, which is the relevant question for a drug people use for decades.

Day 2-4: first perceptible weakening. Day 10-14: full effect, and the correct time to assess and top up. Week 8-12: effect begins to wane as sprouting restores transmission. Month 3-4: return to baseline and retreatment. Daxibotulinumtoxin A was developed specifically to extend that window and its phase 3 programme reports longer duration.

Toxin plus filler is the standard combination in aesthetic practice and the logic is anatomical rather than pharmacological: toxin handles dynamic lines produced by muscle activity, filler handles static folds produced by volume loss, and most faces have both. Treating the frontalis without also treating the glabellar complex is one of the commonest technical errors and a frequent cause of brow ptosis, because you have weakened the brow elevator while leaving the depressors intact. Aminoglycoside antibiotics impair neuromuscular transmission and can potentiate the toxin, which matters if someone is on gentamicin. All topical SNARE peptides — Argireline, SNAP-8, Leuphasyl, Syn-Ake, Vialox — are redundant over a chemically denervated muscle; there is nothing left for them to inhibit. Where they might still have a role is in untreated areas, or in people who want something in the interval between treatments, and the honest framing there is that the effect is small.

This is the benchmark and everything else in this class loses to it, which is the most useful thing the site can say about the topical neuromuscular peptides. Botulinum toxin has phase 3 randomised placebo-controlled registration trials, decades of therapeutic use across dystonia, spasticity, hyperhidrosis and chronic migraine, head-to-head non-inferiority data between products, and repeated-treatment safety data. Argireline has one small developer-run study and a penetration measurement showing 0.01% of applied dose reaches viable epidermis. Presenting a topical peptide as an alternative to toxin is not a matter of degree, it is a different category of intervention. The one honest thing to say for the peptides is that they are cheap, non-invasive and carry essentially no risk — which is the trade being made, and it is a legitimate trade for someone who does not want injections, as long as they know what they are buying.

$60–$200/month. In the US a glabellar treatment typically runs $250-600 and lasts three to four months, so $60-200 a month amortised; multi-area treatments run higher. Pricing varies enormously by market and by whether you are charged per unit or per area. Market observation, not a sourced pricing study.

• ?Participant numbers for the individual registration trials were not confirmed in this session; the trials themselves are verified as existing and indexed.
• ?The exact unit conversion between abobotulinumtoxinA and onabotulinumtoxinA is conventionally taken as 2.5-3:1 but varies by indication and by source, and no official conversion factor exists.
• ?The true incidence of neutralising antibody formation with modern cosmetic dosing is low and imprecisely characterised.
• ?The 150 kDa molecular weight and 1296-residue length in the Core record are the standard published figures for botulinum neurotoxin type A but were not confirmed against a primary source in this session.
• ?Whether the complexing-protein-free formulation genuinely reduces antibody formation in cosmetic practice, as opposed to in theory, is still debated.

• A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, Walker P, Eadie N, Journal of the American Academy of Dermatology, 2002 · PMID 12063480

  One of the two pivotal registration trials for the cosmetic indication.

• Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N, Plastic and Reconstructive Surgery, 2003 · PMID 12973229

  The companion pivotal trial.

• DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2) Carruthers JD, Fagien S, Joseph JH, et al., Plastic and Reconstructive Surgery, 2020 · PMID 31609882

  The longer-duration formulation's phase 3 programme.

• Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines Carruthers A, Carruthers J, Coleman WP 3rd, et al., Dermatologic Surgery, 2013 · PMID 23379292

  Relevant to the antibody-formation question, since this formulation omits the complexing proteins.

• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients Rzany BJ, Ascher B, Avelar RL, et al., Aesthetic Surgery Journal, 2020 · PMID 30951166

  Direct head-to-head comparison between two toxin products.

• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines Carruthers J, Rivkin A, Donofrio L, et al., Dermatologic Surgery, 2015 · PMID 25993609

  Repeated-treatment safety, which is the real-world question.

• Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial Moers-Carpi M, Carruthers J, Fagien S, et al., Dermatologic Surgery, 2015 · PMID 25485803

  Covers the lateral canthal indication and the combination approach with glabella.